Patents by Inventor Frederic Henri Jung

Frederic Henri Jung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9567358
    Abstract: Quinazoline derivatives of formula (I): wherein A is 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: February 14, 2017
    Assignee: AstraZeneca AB
    Inventors: Nicola Murdoch Heron, Frederic Henri Jung, Andrew Mortlock, Georges Pasquet
  • Publication number: 20150307534
    Abstract: Quinazoline derivatives of formula (I): wherein A is 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.
    Type: Application
    Filed: March 18, 2015
    Publication date: October 29, 2015
    Applicant: AstraZeneca AB
    Inventors: Nicola Murdoch HERON, Frederic Henri JUNG, Andrew MORTLOCK, Georges PASQUET
  • Patent number: 9018191
    Abstract: Quinazoline derivatives of formula (I): wherein A is 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: April 28, 2015
    Assignee: AstraZeneca AB
    Inventors: Nicola Murdoch Heron, Andrew Austen Mortlock, Frederic Henri Jung, Georges Rene Pasquet
  • Publication number: 20140162984
    Abstract: Quinazoline derivatives of formula (I): wherein A is 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.
    Type: Application
    Filed: August 21, 2012
    Publication date: June 12, 2014
    Applicant: ASTRAZENECA AB
    Inventors: Nicola Murdoch HERON, Andrew Austen MORTLOCK, Frederic Henri JUNG, Georges Rene PASQUET
  • Patent number: 8268841
    Abstract: Quinazoline derivatives of formula (I): wherein A is 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: September 18, 2012
    Assignee: Astrazeneca AB
    Inventors: Nicola Murdoch Heron, Andrew Austen Mortlock, Frederic Henri Jung, Georges Rene Pasquet
  • Publication number: 20120165351
    Abstract: The invention concerns quinazoline derivatives of Formula I or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.
    Type: Application
    Filed: March 2, 2012
    Publication date: June 28, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Patrick Ple, Frederic Henri Jung
  • Patent number: 8153643
    Abstract: The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: April 10, 2012
    Assignee: AstraZeneca AB
    Inventors: Patrick Ple, Frederic Henri Jung
  • Patent number: 7973164
    Abstract: The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: July 5, 2011
    Assignee: AstraZeneca AB
    Inventors: Frederic Henri Jung, Patrick Ple
  • Patent number: 7709479
    Abstract: The use of a compound of formula (I) or a salt, ester, amide or prodrug thereof; where X is O, or S, S(O) or S(O)2, NH or NR12 where R12 is hydrogen or C1-6 alkyl; R5 is selected from a group NHC(O)OR9, NHC(O)R9, NHS(O)2R9, C(O)R9, C(O)OR9, S(O)R9, S(O)OR9, S(O)2OR9, C(O)NR10 R11, S(O)NR10R11 S(O)ONR10R11, where R9, R10 or R11 are various specified organic groups; R6 is hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl; R7 and R8 are various specified organic groups, and R1, R2, R3, R4 are independently selected from halogeno, cyano, nitro, C1-3alkylsulphanyl, —N(OH)R13— (wherein R7 is hydrogen, or C1-3alkyl), or R15X1— (wherein X1 represents a direct bond, —O—, —CH2—, —OCO—, carbonyl, —S—, —SO—, —SO2—, —NR16CO—, —CONR16—, —SO2NR16—, —NR17SO2— or —NR18— (wherein R16, R17 and R18 each independently represents hydrogen, C1-3alkyl or C1-3alkoxy C2-3alkyl), and R9 is hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: May 4, 2010
    Assignee: AstraZeneca
    Inventors: Andrew Austen Mortlock, Nicholas John Keen, Frederic Henri Jung, Andrew George Brewster
  • Publication number: 20100105655
    Abstract: There is provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: October 28, 2009
    Publication date: April 29, 2010
    Inventors: Richard Ducray, Clifford David Jones, Frédéric Henri Jung, Iain Simpson
  • Patent number: 7691867
    Abstract: Quinazoline derivatives of formula (I); for use in the treatment of proliferative diseases such as cancer and in the preparation of medicaments for use in the treatment of proliferative diseases, and to process for their preparation, as well as pharmaceutical compositions containing them as active ingredient.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: April 6, 2010
    Assignee: AstraZeneca AB
    Inventors: Nicola Murdoch Heron, Georges Rene Pasquet, Andrew Austen Mortlock, Frederic Henri Jung
  • Publication number: 20100069412
    Abstract: Quinazoline derivatives of formula (I): wherein A is 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.
    Type: Application
    Filed: April 28, 2009
    Publication date: March 18, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Nicola Murdoch Heron, Andrew Austen Mortlock, Frederic Henri JUNG, Georges Rene PASQUET
  • Publication number: 20090233924
    Abstract: The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.
    Type: Application
    Filed: October 7, 2005
    Publication date: September 17, 2009
    Inventors: Patrick Ple, Frederic Henri Jung
  • Publication number: 20090233950
    Abstract: The invention concerns quinazoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: March 1, 2007
    Publication date: September 17, 2009
    Inventors: Frederic Henri Jung, Patrick Ple
  • Publication number: 20090215770
    Abstract: The invention provides quinazoline derivatives of formula (I): in the preparation of a medicament for use in the inhibition of Aurora kinase and also novel quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: May 28, 2008
    Publication date: August 27, 2009
    Applicant: AstraZeneca AB
    Inventors: Frederic Henri Jung, Georges Rene Pasquet
  • Publication number: 20090076075
    Abstract: The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: March 1, 2007
    Publication date: March 19, 2009
    Inventors: Frederic Henri Jung, Remy Robert Morgentin, Patrick Ple
  • Publication number: 20090076074
    Abstract: The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: March 1, 2007
    Publication date: March 19, 2009
    Inventors: Frederic Henri Jung, Patrick Ple
  • Publication number: 20090042910
    Abstract: The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: March 1, 2007
    Publication date: February 12, 2009
    Inventors: Frederic Henri Jung, Patrick Ple
  • Publication number: 20090036474
    Abstract: The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.
    Type: Application
    Filed: October 7, 2005
    Publication date: February 5, 2009
    Inventors: Patrick Ple, Frederic Henri Jung
  • Publication number: 20090036485
    Abstract: The invention concerns quinoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.
    Type: Application
    Filed: October 7, 2005
    Publication date: February 5, 2009
    Inventor: Frederic Henri Jung